
## Alexi A Wright

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7074073/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Associations Between End-of-Life Discussions, Patient Mental Health, Medical Care Near Death, and Caregiver Bereavement Adjustment. JAMA - Journal of the American Medical Association, 2008, 300, 1665.	3.8	2,213
2	Landscape of genomic alterations in cervical carcinomas. Nature, 2014, 506, 371-375.	13.7	708
3	End-of-Life Discussions, Goal Attainment, and Distress at the End of Life: Predictors and Outcomes of Receipt of Care Consistent With Preferences. Journal of Clinical Oncology, 2010, 28, 1203-1208.	0.8	685
4	Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health. Journal of Clinical Oncology, 2010, 28, 4457-4464.	0.8	671
5	Provision of Spiritual Care to Patients With Advanced Cancer: Associations With Medical Care and Quality of Life Near Death. Journal of Clinical Oncology, 2010, 28, 445-452.	0.8	383
6	Religious Coping and Use of Intensive Life-Prolonging Care Near Death in Patients With Advanced Cancer. JAMA - Journal of the American Medical Association, 2009, 301, 1140.	3.8	346
7	Family Perspectives on Aggressive Cancer Care Near the End of Life. JAMA - Journal of the American Medical Association, 2016, 315, 284.	3.8	341
8	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 3460-3473.	0.8	318
9	Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ, The, 2014, 348, g1219-g1219.	3.0	257
10	Provision of Spiritual Support to Patients With Advanced Cancer by Religious Communities and Associations With Medical Care at the End of Life. JAMA Internal Medicine, 2013, 173, 1109.	2.6	242
11	Oncogenic mutations in cervical cancer. Cancer, 2013, 119, 3776-3783.	2.0	225
12	Support of cancer patients' spiritual needs and associations with medical care costs at the end of life. Cancer, 2011, 117, 5383-5391.	2.0	222
13	Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecologic Oncology, 2016, 143, 3-15.	0.6	208
14	"lf God Wanted Me Yesterday, I Wouldn't Be Here Today― Religious and Spiritual Themes in Patients' Experiences of Advanced Cancer. Journal of Palliative Medicine, 2010, 13, 581-588.	0.6	173
15	Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. Journal of Clinical Oncology, 2015, 33, 2841-2847.	0.8	159
16	Beyond Burnout — Redesigning Care to Restore Meaning and Sanity for Physicians. New England Journal of Medicine, 2018, 378, 309-311.	13.9	154
17	Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. Journal of Clinical Oncology, 2019, 37, 2786-2794.	0.8	154
18	Medical Oncologists' Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study. Journal of Clinical Oncology, 2018, 36, 1957-1962.	0.8	150

#	Article	IF	CITATIONS
19	End-of-Life Care for Blood Cancers: A Series of Focus Groups With Hematologic Oncologists. Journal of Oncology Practice, 2014, 10, e396-e403.	2.5	142
20	Mental health, treatment preferences, advance care planning, location, and quality of death in advanced cancer patients with dependent children. Cancer, 2009, 115, 399-409.	2.0	125
21	Influence of patients' preferences and treatment site on cancer patients' endâ€ofâ€life care. Cancer, 2010, 116, 4656-4663.	2.0	112
22	Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. Journal of Clinical Oncology, 2016, 34, 3854-3863.	0.8	112
23	Trends in Advance Care Planning in Patients With Cancer. JAMA Oncology, 2015, 1, 601.	3.4	110
24	Threats of Bots and Other Bad Actors to Data Quality Following Research Participant Recruitment Through Social Media: Cross-Sectional Questionnaire. Journal of Medical Internet Research, 2020, 22, e23021.	2.1	109
25	Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: The TEACHH model. Cancer, 2014, 120, 134-141.	2.0	106
26	Home Testing for HIV. New England Journal of Medicine, 2006, 354, 437-440.	13.9	102
27	Human cytotrophoblasts acquire aneuploidies as they differentiate to an invasive phenotype. Developmental Biology, 2005, 279, 420-432.	0.9	88
28	Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. Journal of Clinical Oncology, 2021, 39, 1531-1539.	0.8	88
29	Letting Go of the Rope — Aggressive Treatment, Hospice Care, and Open Access. New England Journal of Medicine, 2007, 357, 324-327.	13.9	82
30	Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer. JAMA Oncology, 2017, 3, 76.	3.4	77
31	Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. Journal of Clinical Oncology, 2015, 33, 2908-2913.	0.8	76
32	Family Perspectives on Hospice Care Experiences of Patients with Cancer. Journal of Clinical Oncology, 2017, 35, 432-439.	0.8	72
33	Understanding Treatment Refusal Among Adults Presenting for HIV-Testing in Soweto, South Africa: A Qualitative Study. AIDS and Behavior, 2015, 19, 704-714.	1.4	70
34	The HOPE Pilot Study: Harnessing Patient-Reported Outcomes and Biometric Data to Enhance Cancer Care. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	1.0	67
35	End-of-Life Care for Older Patients With Ovarian Cancer Is Intensive Despite High Rates of Hospice Use. Journal of Clinical Oncology, 2014, 32, 3534-3539.	0.8	63
36	Roe versus Reality — Abortion and Women's Health. New England Journal of Medicine, 2006, 355, 1-9.	13.9	56

#	Article	IF	CITATIONS
37	The Influence of Age on the Likelihood of Receiving End-of-Life Care Consistent with Patient Treatment Preferences. Journal of Palliative Medicine, 2010, 13, 719-726.	0.6	55
38	Bar Coding for Patient Safety. New England Journal of Medicine, 2005, 353, 329-331.	13.9	53
39	US Trends in Opioid Access Among Patients With Poor Prognosis Cancer Near the End-of-Life. Journal of Clinical Oncology, 2021, 39, 2948-2958.	0.8	53
40	Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecologic Oncology, 2015, 138, 201-206.	0.6	52
41	Preventing Cervical Cancer in the Developing World. New England Journal of Medicine, 2006, 354, 1110-1110.	13.9	48
42	PEPFAR in Transition — Implications for HIV Care in South Africa. New England Journal of Medicine, 2013, 369, 1385-1387.	13.9	48
43	Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer, 2016, 122, 3127-3135.	2.0	46
44	Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncology, 2016, 2, 1427.	3.4	45
45	Tobacco Tightrope — Balancing Disease Prevention and Economic Development in China. New England Journal of Medicine, 2007, 356, 1493-1496.	13.9	42
46	A Qualitative Analysis of Factors Influencing HPV Vaccine Uptake in Soweto, South Africa among Adolescents and Their Caregivers. PLoS ONE, 2013, 8, e72094.	1.1	42
47	Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer. Cancer, 2018, 124, 176-182.	2.0	42
48	Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecologic Oncology, 2020, 159, 72-78.	0.6	41
49	Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival. PLoS ONE, 2018, 13, e0193047.	1.1	41
50	Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecologic Oncology, 2018, 150, 451-459.	0.6	33
51	Cancer patients' experiences with medicinal cannabis–related care. Cancer, 2021, 127, 67-73.	2.0	32
52	Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecologic Oncology, 2019, 154, 95-101.	0.6	29
53	Circumcision — A Surgical Strategy for HIV Prevention in Africa. New England Journal of Medicine, 2008, 359, 2412-2415.	13.9	26
54	Minor Cognitive Impairments in Cancer Patients Magnify the Effect of Caregiver Preferences on End-of-Life Care. Journal of Pain and Symptom Management, 2013, 45, 650-659.	0.6	23

#	Article	IF	CITATIONS
55	Natural Language Processing to Assess Palliative Care and End-of-Life Process Measures in Patients With Breast Cancer With Leptomeningeal Disease. American Journal of Hospice and Palliative Medicine, 2020, 37, 371-376.	0.8	23
56	Patterns and predictors of cancerâ€related fatigue in ovarian and endometrial cancers: 1â€year longitudinal study. Cancer, 2020, 126, 3526-3533.	2.0	23
57	Processes of Discontinuing Chemotherapy for Metastatic Non–Small-Cell Lung Cancer at the End of Life. Journal of Oncology Practice, 2015, 11, e405-e412.	2.5	20
58	Documentation of Palliative and End-of-Life Care Process Measures Among Young Adults Who Died of Cancer: A Natural Language Processing Approach. Journal of Adolescent and Young Adult Oncology, 2020, 9, 100-104.	0.7	20
59	The Relationship of Obesity to Hospice Use and Expenditures. Annals of Internal Medicine, 2017, 166, 381.	2.0	19
60	Outcomes of secondary cytoreductive surgery forÂpatients with platinum-sensitive recurrent ovarianÂcancer. American Journal of Obstetrics and Gynecology, 2019, 221, 625.e1-625.e14.	0.7	18
61	The Affordable Care Act and End-of-Life Care for Patients With Cancer. Cancer Journal (Sudbury, Mass) Tj ETQq1	1 0.7843 1.0	14 rgBT /Ove
62	Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecologic Oncology Reports, 2019, 29, 118-122.	0.3	17
63	United States Acculturation and Cancer Patients' End-of-Life Care. PLoS ONE, 2013, 8, e58663.	1.1	16
64	Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer. Gynecologic Oncology, 2021, 163, 408-418.	0.6	16
65	Yoga for chronic chemotherapy-induced peripheral neuropathy pain: a pilot, randomized controlled trial. Journal of Cancer Survivorship, 2022, 16, 882-891.	1.5	14
66	Evaluation of Reliability and Correlations of Quality Measures in Cancer Care. JAMA Network Open, 2021, 4, e212474.	2.8	12
67	Leveraging mobile health technology and research methodology to optimize patient education and self-management support for advanced cancer pain. Supportive Care in Cancer, 2021, 29, 5741-5751.	1.0	12
68	Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecologic Oncology, 2021, 160, 457-463.	0.6	11
69	Collateral Damage — Médecins sans Frontières Leaves Afghanistan and Iraq. New England Journal of Medicine, 2004, 351, 2571-2573.	13.9	10
70	Scientific Drought, Golden Eggs, and Global Leadership — Why Trump's NIH Funding Cuts Would Be a Disaster. New England Journal of Medicine, 2017, 376, 1701-1704.	13.9	10
71	Reduced Opioid Prescribing by Oncologists: Progress Made, or Ground Lost?. Journal of the National Cancer Institute, 2021, 113, 225-226.	3.0	9
72	Cervical Abnormalities in South African Women Living With HIV With High Screening and Referral Rates. Journal of Global Oncology, 2016, 2, 375-380.	0.5	8

#	Article	IF	CITATIONS
73	Association of Medicaid expansion and insurance status, cancer stage, treatment and mortality among patients with cervical cancer. Cancer Reports, 2021, 4, e1407.	0.6	8
74	Medical Oncologists' Views on the Utility of Medical Marijuana Across the Cancer Trajectory. Journal of Pain and Symptom Management, 2019, 57, e1-e4.	0.6	7
75	How does a single session group intervention improve sexual function in ovarian cancer survivors? A secondary analysis of effects of self-efficacy, knowledge and emotional distress. Psychology, Health and Medicine, 2020, 25, 110-120.	1.3	6
76	Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study. Gynecologic Oncology, 2021, 160, 227-233.	0.6	6
77	Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: Society of Gynecologic Oncology and ASCO Clinical Practice Guideline Summary. Journal of Oncology Practice, 2016, 12, 1254-1257.	2.5	5
78	Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecologic Oncology, 2021, 161, 581-586.	0.6	5
79	Match Point?. New England Journal of Medicine, 2004, 351, 1165-1167.	13.9	4
80	Living Through Ovarian Cancer Treatment. Hematology/Oncology Clinics of North America, 2018, 32, 1073-1085.	0.9	4
81	Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. Gynecologic Oncology, 2015, 138, 712-716.	0.6	3
82	Surveillance in Older Women With Incidental Ovarian Cysts: Maximal Projected Benefits by Age and Comorbidity Level. Journal of the American College of Radiology, 2021, 18, 10-18.	0.9	3
83	Multimodality cancer care and implications for episode-based payments in cancer. American Journal of Managed Care, 2019, 25, 537-538.	0.8	3
84	Developing and Field Testing BOLSTER: A Nurse-Led Care Management Intervention to Support Patients and Caregivers following Hospitalization for Gynecologic Cancer-Associated Peritoneal Carcinomatosis. Journal of Palliative Medicine, 2022, 25, 1367-1375.	0.6	3
85	Pushing the bar in treatment of cervical cancer: What can comprehensive cancer centers do on their own?. Gynecologic Oncology, 2013, 131, 464-466.	0.6	2
86	The SHARE Study: Pilot Study of a Communication Intervention Designed to Elicit Advanced-Stage Cancer Patients' Preferences and Goals. Journal of Palliative Medicine, 2022, 25, 1646-1654.	0.6	2
87	Reply to D. Luvero et al. Journal of Clinical Oncology, 2017, 35, 802-802.	0.8	1
88	Differential patterns of circadian rhythmicity in women with malignant versus benign gynecologic tumors. Psycho-Oncology, 2019, 28, 643-646.	1.0	1
89	Oncologists' perspectives on medical marijuana use by older adults. Journal of Geriatric Oncology, 2020, 11, 1034-1037.	0.5	1
90	Reply to W. E. Rosa et al and T. N. Townsend et al. Journal of Clinical Oncology, 2022, 40, 312-314.	0.8	0